Compare LGIH & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | PSNL |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2013 | 2019 |
| Metric | LGIH | PSNL |
|---|---|---|
| Price | $50.78 | $16.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $75.90 | $12.20 |
| AVG Volume (30 Days) | 222.5K | ★ 3.7M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $1,705,504,000.00 | $69,648,000.00 |
| Revenue This Year | $2.32 | $15.34 |
| Revenue Next Year | $17.94 | $41.46 |
| P/E Ratio | $39.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $4.96 |
| 52 Week High | $66.25 | $18.89 |
| Indicator | LGIH | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 54.47 |
| Support Level | $46.17 | $7.62 |
| Resistance Level | $55.62 | $16.39 |
| Average True Range (ATR) | 1.93 | 0.61 |
| MACD | -0.68 | -0.21 |
| Stochastic Oscillator | 23.60 | 17.68 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.